• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clinical significance of early immunological paralysis in patients with severe H1N1 influenza A

tetano

Editor, Senior Moderator
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017 Jul;29(7):581-585. doi: 10.3760/cma.j.issn.2095-4352.2017.07.002.
[h=1][Clinical significance of early immunological paralysis in patients with severe H1N1 influenza A].[/h] [Article in Chinese]
Qian Y[SUP]1[/SUP], Xie H, Tian R, Lu J, Jin W, Wang R.
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]OBJECTIVE:[/h] To analysis the immunological characteristics of patients with severe H1N1 influenza A, and to provide theoretical basis for predicting the prognosis of the disease.
[h=4]METHODS:[/h] A retrospective analysis was conducted. The clinical data of 15 patients diagnosed with severe H1N1 influenza A and admitted to Shanghai General Hospital of Nanjing Medical University from October 2015 to December 2016 were collected. All the patients were divided into survival and death groups according to 28-day survival. Clinical characteristics, treatment algorithm, organ function, inflammatory reaction and immune cell status were compared, and Cox regression was used to decide the risk factors of 28-day death in patients with severe H1N1 infection A.
[h=4]RESULTS:[/h] All 15 patients with severe H1N1 infection A were enrolled, most of who presented with cough (93.3%), fever (86.7%), sputum production (80.0%), shortness of breath (73.3%), myalgia (40.0%) and fatigue (40.0%). All had been received anti-virus, antibiotics, mechanical ventilation and anti-coagulation therapy; some were treated with prone position, neuromuscular blocker and extracorporeal membrane oxygenation (ECMO). The incidences of acute myocardial and kidney injury were high, and the acute physiology and chronic health evaluation II (APACHE II) score (14.1?6.1) and sequential organ failure assessment (SOFA) score (9.6?4.1) implicated the critical condition. Of 15 patients, 4 patients died in 28 days, while 11 were cured and discharged. Compared with survival group, the patients in death group had higher levels of APACHE II score (22.7?3.8 vs. 11.8?3.8), troponin [cTn (μg/L): 0.52 (0.07, 2.02) vs. 0.15 (0.10, 0.45)] and blood urea nitrogen [BUN (mmol/L): 11.9 (6.7, 29.1) vs. 3.9 (2.7, 6.8)] and a lower level of blood platelets count [PLT (?10[SUP]9[/SUP]/L): 76?33 vs. 146?49, all P < 0.05]. The levels of C-reactive protein (CRP) and interleukin-6 (IL-6) within 24 hours of admission in death group were significantly higher than those of survival group [CRP (mg/L): 172.2?88.5 vs. 74.8?33.1, IL-6 (ng/L): 283.3 (140.1, 711.0) vs. 18.5 (12.7, 71.4), both P < 0.01]. Compared with survival group, the expressions of CD3[SUP]+[/SUP], CD4[SUP]+[/SUP], CD8[SUP]+[/SUP] T cells and natural killer cell (NK cell) in death group were significantly decreased (CD3[SUP]+[/SUP] T cell: 0.348?0.119 vs. 0.573?0.106, CD4[SUP]+[/SUP] T cell: 0.135?0.046 vs. 0.344?0.098, CD8[SUP]+[/SUP] T cell: 0.089?0.057 vs. 0.208?0.054, NK cell: 0.124?0.057 vs. 0.252?0.182, all P < 0.05), but there were no significant differences in CD4[SUP]+[/SUP]/CD8[SUP]+[/SUP] ratio and human leucocyte antigen-DR positive (HLA-DR[SUP]+[/SUP]) T cell between death group and survival group (CD4[SUP]+[/SUP]/CD8[SUP]+[/SUP] ratio: 1.57?0.26 vs. 1.83?0.54, HLA-DR[SUP]+[/SUP] T cell: 0.035?0.022 vs. 0.062?0.036, both P > 0.05). B lymphocyte in death group was significantly higher than that of survival group (0.477?0.136 vs. 0.229?0.121, P < 0.01). Cox regression analysis revealed that APACHE II score [risk ratio (RR) = 20.4, 95% confidence interval (95%CI) = 5.3-31.2, P = 0.017], CD4[SUP]+[/SUP] T cell (RR = 11.1, 95%CI = 5.1-20.0, P = 0.048) and CD8[SUP]+[/SUP] T cell (RR = 9.1, 95%CI = 4.3-16.7, P = 0.049) were independently risk factors of 28-day survival of patients with severe H1N1 influenza A.
[h=4]CONCLUSIONS:[/h] Immunological paralysis and severe inflammatory response were early complicated with severe H1N1 influenza A, and these were significantly associated with prognosis.


PMID: 28743332 DOI: 10.3760/cma.j.issn.2095-4352.2017.07.002
 
Back
Top